All three abstracts submitted by Desentum have been accepted for oral presentations at the annual congress of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Glasgow, UK, on Jun 13–16, 2025. Two of the presentations will showcase the latest clinical results of the investigational birch pollen allergy vaccine DM-101PX, while the third one will focus on Desentum’s recent scientific discoveries about the interaction of peanut allergen Ara h 2 with IgE antibodies.
“We are excited to share our findings with the scientific community”, says Pekka Mattila, CEO of Desentum. “The Phase I clinical results provide a strong foundation for advancing the birch pollen allergy vaccine to clinical Phase II scheduled to start this year. In peanut allergy, our research increases the understanding of the molecular mechanism of allergen-IgE interaction, offering valuable insights for the development of a safe and effective immunotherapy.”
The details of the presentations are:
Friday 13 June 2025 at 16:45–18:15, FlashTalk 06 – Mechanisms and applications in allergy and asthma research
Detection of blocking antibodies using a basophil activation test in sera from allergic patients treated with investigational birch pollen allergy vaccine DM-101PX
Presenter: Dr Janneke Ruinemans-Koerts, Rijnstate Hospital, The Netherlands
Saturday 14 June 2025 at 15:00–16:30, Oral Abstract Session 09 – Progress in understanding the mechanisms of airborne allergen immunotherapy
Subcutaneous AIT with a thermosensitive hydrogel formulation containing genetically engineered Bet v 1 is safe and induces a strong protective immune response in birch pollen allergic patients
Presenter: Dr Anne Marie Salapatek, Cliantha Research, Canada
Saturday 14 June 2025 at 15:00–16:30, Oral Abstract Session 10 – Understanding of mechanisms of food immunotherapy
Structural analysis of IgE epitopes of Ara h 2 reveals simultaneous binding of three copies of a human derived IgE Fab fragment to the major peanut allergen
Presenter: Prof. Juha Rouvinen, University of Eastern Finland, Finland
About DM-101PX
DM-101PX is an investigational medicinal product intended for immunotherapeutic treatment of birch pollen allergy. The active ingredient is DM-101, a recombinant variant of major birch pollen allergen Bet v 1, which is genetically engineered to reduce its allergenicity while retaining the desired immunological properties. In DM-101PX, it is formulated into a thermosensitive hydrogel to support the controlled release of the active ingredient after subcutaneous injection.
About Desentum
Desentum Oy is a clinical-stage biopharmaceutical company based in Espoo, Finland, leveraging high-resolution protein engineering and drug delivery technologies for designing allergy vaccines that enable short-course treatment to restore long-term tolerance. Desentum, founded in 2011, is a spin-off company from VTT Technical Research Centre of Finland Ltd. With its product development, Desentum targets both respiratory and food allergies.
